Editor’s note: Current Dark Daily’s articles have moved to their new home on Today’s Clinical Lab.
Clinical laboratory leaders and pathologists may soon have access to a disruptive new tool in the fight against early-stage disease. Researchers at UCLA have developed MethylScan, a low-cost blood test capable of detecting multiple cancers and liver diseases simultaneously by analyzing DNA methylation patterns in cell-free DNA (cfDNA).
While traditional liquid biopsies often rely on detecting rare genetic mutations—a process that requires expensive, deep sequencing—MethylScan shifts the focus to epigenetic markers. By targeting chemical signals that regulate gene activity, the test can identify not only the presence of disease but also its tissue of origin.
Solving the ‘Noise’ Problem in cfDNA
The primary hurdle for affordable liquid biopsies has been "genomic noise." Roughly 80% to 90% of cfDNA in the blood originates from normal blood cells, making it difficult to find the faint signals of early-stage tumors. The UCLA team, led by Dr. Jasmine Zhou and Dr. Wenyuan Li, developed a proprietary enrichment method that involves:
- Selective cleavage: Specialized enzymes cut away unmethylated DNA (primarily from healthy blood cells).
- Signal enrichment: A genome-wide hybridization panel enriches the sample for methylated DNA from solid organs.
- Cost reduction: This reduction in "noise" allows for effective sequencing with significantly less data. Researchers estimate that if sequencing costs continue to fall, the test could eventually be performed for under $20.
Clinical Performance and Multi-Organ Utility
In a study of 1,061 participants published in the journal PNAS, MethylScan demonstrated robust diagnostic accuracy across a variety of conditions:
- Cancer detection: At 98% specificity, the test identified 63% of cancers across all stages and 55% of early-stage cases (liver, lung, ovarian, and stomach).
- Hepatocellular carcinoma (HCC): For high-risk groups (cirrhosis or hepatitis B virus), it detected nearly 80% of cases.
- Beyond cancer: The test successfully distinguished between various liver diseases—including viral hepatitis and metabolic-associated liver disease—with 85% accuracy.
Clinical Laboratory Implications
For clinical laboratory professionals, MethylScan offers one example of the potential to transform the lab from a site of reactive testing to a hub for system-wide health monitoring. Because the test tracks organ stress and methylation shifts before physical symptoms or tumor masses appear, it could eventually replace more invasive diagnostic procedures, such as liver biopsies.
While larger prospective trials are required before MethylScan sees widespread clinical adoption, the UCLA study proves that a single, affordable assay for universal disease detection is no longer a distant long shot, but a looming reality for the diagnostic industry.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
